Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma

NCT05526924 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT05526924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05526924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Recruiting
Start date
March 7, 2023
Completion date
January 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck cancer stage iv, head and neck cancers - throat, head and neck carcinoma, head and neck squamous cell carcinoma